



261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Vermont Kind
License Number: SCLT0186 MANU0027

Sample ID: 20250925-24607
Sample Name: Tar Pit x Oilspill Virgin Extract
Sample Lot: MANU0027-C0098
Sample Matrix: Solvent Extraction Concentrates
Date Received: 10/2/2025
Date Reported: 10/7/2025
Date Tested: 10/3/2025



Total Terpenes (%) : 6.4105

Dominant Terpenes (%)

beta-caryophyllene	2.2451
Myrcene	1.2035
alpha-Bisabolol	0.851
alpha-Humulene	0.7517
alpha-Pinene	0.3361

Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #80459

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.851	8.51	0.000003	0.001
alpha-Humulene	0.7517	7.517	0.000002	0.001
alpha-Pinene	0.3361	3.361	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	0.012	0.12	0.000004	0.001
beta-caryophyllene	2.2451	22.451	0.000004	0.001
beta-Pinene	0.1552	1.552	0.000002	0.001
Camphene	ND	ND	0.000001	0.001
Caryophyllene Oxide	0.1628	1.628	0.000011	0.001
Eucalyptol	0.0472	0.472	0.000002	0.001
gamma-Terpinene	0.0159	0.159	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	0.0333	0.333	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.2496	2.496	0.000002	0.001
Linalool	0.1471	1.471	0.000003	0.001
Nerolidol	0.1074	1.074	0.000007	0.001
Myrcene	1.2035	12.035	0.000003	0.001
Ocimene	0.0926	0.926	0.000002	0.001
Total Terpenes	6.4105	64.105		



Callie Chapman

Callie Chapman
 Lab Director
 10/7/2025

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

